Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Mar. Drugs 2013, 11(12), 5159-5189; doi:10.3390/md11125159
Article

Synthesis and Neuroprotective Action of Xyloketal Derivatives in Parkinson’s Disease Models

1
, 2
, 2
, 1
, 1
, 2
, 1
, 2
, 1,* , 1
, 1
 and 1,*
Received: 1 November 2013; in revised form: 2 December 2013 / Accepted: 4 December 2013 / Published: 18 December 2013
View Full-Text   |   Download PDF [1444 KB, updated 19 December 2013; original version uploaded 18 December 2013]
Abstract: Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting people over age 55. Oxidative stress actively participates in the dopaminergic (DA) neuron degeneration of PD. Xyloketals are a series of natural compounds from marine mangrove fungus strain No. 2508 that have been reported to protect against neurotoxicity through their antioxidant properties. However, their protection versus 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity is only modest, and appropriate structural modifications are necessary to discover better candidates for treating PD. In this work, we designed and synthesized 39 novel xyloketal derivatives (139) in addition to the previously reported compound, xyloketal B. The neuroprotective activities of all 40 compounds were evaluated in vivo via respiratory burst assays and longevity-extending assays. During the zebrafish respiratory burst assay, compounds 1, 9, 23, 24, 36 and 39 strongly attenuated reactive oxygen species (ROS) generation at 50 μM. In the Caenorhabditis elegans longevity-extending assay, compounds 1, 8, 15, 16 and 36 significantly extended the survival rates (p < 0.005 vs. dimethyl sulfoxide (DMSO)). A total of 15 compounds were tested for the treatment of Parkinson’s disease using the MPP+-induced C. elegans model, and compounds 1 and 8 exhibited the highest activities (p < 0.005 vs. MPP+). In the MPP+-induced C57BL/6 mouse PD model, 40 mg/kg of 1 and 8 protected against MPP+-induced dopaminergic neurodegeneration and increased the number of DA neurons from 53% for the MPP+ group to 78% and 74%, respectively (p < 0.001 vs. MPP+ group). Thus, these derivatives are novel candidates for the treatment of PD.
Keywords: xyloketal; Caenorhabditis elegans; zebrafish; C57BL/6; Parkinson’s disease xyloketal; Caenorhabditis elegans; zebrafish; C57BL/6; Parkinson’s disease
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Li, S.; Shen, C.; Guo, W.; Zhang, X.; Liu, S.; Liang, F.; Xu, Z.; Pei, Z.; Song, H.; Qiu, L.; Lin, Y.; Pang, J. Synthesis and Neuroprotective Action of Xyloketal Derivatives in Parkinson’s Disease Models. Mar. Drugs 2013, 11, 5159-5189.

AMA Style

Li S, Shen C, Guo W, Zhang X, Liu S, Liang F, Xu Z, Pei Z, Song H, Qiu L, Lin Y, Pang J. Synthesis and Neuroprotective Action of Xyloketal Derivatives in Parkinson’s Disease Models. Marine Drugs. 2013; 11(12):5159-5189.

Chicago/Turabian Style

Li, Shichang; Shen, Cunzhou; Guo, Wenyuan; Zhang, Xuefei; Liu, Shixin; Liang, Fengyin; Xu, Zhongliang; Pei, Zhong; Song, Huacan; Qiu, Liqin; Lin, Yongcheng; Pang, Jiyan. 2013. "Synthesis and Neuroprotective Action of Xyloketal Derivatives in Parkinson’s Disease Models." Mar. Drugs 11, no. 12: 5159-5189.


Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert